PUK7 DELIVERING TREATMENT EFFECTIVENESS: COSTS AND PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF OAB IN FIVE EUROPEAN COUNTRIES

@inproceedings{Reeves2005PUK7DT,
  title={PUK7 DELIVERING TREATMENT EFFECTIVENESS: COSTS AND PERSISTENCE OF TOLTERODINE IN THE MANAGEMENT OF OAB IN FIVE EUROPEAN COUNTRIES},
  author={Penny Reeves and Zoe S. Kopp and A. Resch and Ian Milsom and C. J. Kelleher and Walter Artibani},
  year={2005}
}
parameters with p < 0.001. Compared to MMF, reduced-dose of CsA with everolimus decreased the one-year total direct medical cost due to major clinical events by HF 1,373,254 and HF 1,387,057 for everolimus 1.5mg and 3.0mg, respectively (see table) . Adjusted for patient characteristics, the cost savings become HF 940,380 for everolimus 1.5mg and HF 838,570 for everolimus 3.0mg. CONCLUSION: The use of reduced-dose CsA with everolimus 1.5mg in de novo kidney transplant recipients improves… CONTINUE READING

Topics from this paper.